AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture

Inclusion Criteria:

- Subjects with a diagnosis of Dupuytren's contracture, with a fixed flexion deformity
of at least one finger, other than the thumb, that had a contracture at least 20°, but
not greater than 100°, for MP (80° for PIP) joints, caused by a palpable cord that had
never been treated with AA4500.

- Had a positive "table top test," defined as the inability to simultaneously place the
affected finger(s) and palm flat against a table top.

- Judged to be in good health.

Exclusion Criteria:

- Had a chronic muscular, neurological, or neuromuscular disorder that affected the
hands.

- Had received a treatment for Dupuytren's contracture, including surgery (fasciectomy
or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil
and/or interferon on the selected primary joint within 90 days before the first dose
of study drug.

- Had a known recent history of stroke, bleeding, a disease process that affected the
hands, or other medical condition, which in the investigator's opinion, would make the
subject unsuitable for enrollment in the study.